ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL)

Leukemia & Lymphoma
V SilingardiD Vallisa

Abstract

A randomized trial was designed in order to compare the efficacy and feasibility of ProMECE-CytaBOM (P-C) and MACOP-B (M-B) in patients with advanced, aggressive non Hodgkin's lymphoma (NHL). P-C and M-B were chosen due to their association with a very high complete remission rate when compared to other published protocols. The study was conducted on 210 patients with intermediate or high-grade NHL in stage I bulky, or stages II-IV, randomized to receive either 6 courses of P-C delivered every 28 days (106 patients), or 12 weeks of M-B chemotherapy (104 patients). In both regimens doxorubicin was replaced by a 20% higher dose of epidoxorubicin (i.e. 30 mg/m2 of the analog). At the end of induction therapy patients could receive additional radiotherapy to residual masses or to sites of previous bulky disease. The two groups of patients were compared for response rates, number and severity of therapy related side effects, overall survival, disease-free survival, and time to treatment failure. Sixty-five patients (62%) treated with P-C and 69 patients (67%) treated with M-B achieved a complete remission, with no significant differences between the two treatment arms (P = 0.13). The overall objective response rate (complete + parti...Continue Reading

References

Jan 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M SchneiderB D Clarkson
Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T P MillerR I Fisher
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerM D Goodyear
Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H Cohen
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D B BoydD McDermott
Oct 1, 1989·European Journal of Cancer & Clinical Oncology·U VitoloG Luxi
May 1, 1985·Annals of Internal Medicine·P Klimo, J M Connors
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I A CooperF C Firkin
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Apr 8, 1993·The New England Journal of Medicine·J O Armitage

❮ Previous
Next ❯

Citations

Nov 19, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BariM C Cox
Feb 1, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G GobbiUNKNOWN Gruppo Italiano Studio Linfomi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.